Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy

  • Lin, Gui-Nan (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital) ;
  • Jiang, Xiao-Mei (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital) ;
  • Peng, Jie-Wen (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital) ;
  • Xiao, Jian-Jun (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital) ;
  • Liu, Dong-Ying (Department of Clinical Oncology, Jiangmen Hospital of Sun Yat-sen University, Jiangmen City Central Hospital) ;
  • Xia, Zhong-Jun (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The prognostic significance of the circulating absolute monocyte count (AMC) in patients with locally advanced hepatocellular carcinoma (HCC) is uncertain. This study was designed to assess the association of circulating AMC with survival outcomes in patients diagnosed with locally advanced or metastatic HCC receiving systemic chemotherapy. Materials and Methods: Between January 1, 2005 and December 30, 2012, locally advanced or metastatic HCC patients who had Child-Pugh stage A or B disease and received systemic chemotherapy were retrospectively enrolled. Patient features including gender, age, extrahepatic metastasis, Child-Pugh stage, serum alpha-fetoprotein(AFP) level and AMC were collected to investigate their prognostic impact on overall survival(OS). Results: A total of 216 patients were eligible for the study. The optimal cut-off value of AMC for OS analysis was $0.38{\times}10^9/L$. Median OS was 5.84 months in low-AMC group (95% confidence interval [CI], 5.23 to 6.45), and 5.21 months in high-AMC group (95% CI, 4.37 to 6.04; p=0.003). In COX multivariate analysis, elevated AMC remained as an independent prognostic factor for worse OS (HR, 1.578; 95% CI, 1.120 to 2.223, p=0.009). Conclusions: Our results indiicate that circulating AMC is confirmed to be an independent prognostic factor for OS in patients with locally advanced or metastatic HCC receiving systemic chemotherapy.

Keywords

References

  1. Benetti A, Berenzi A, Gambarotti M, et al (2008). Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res, 68, 8626-34. https://doi.org/10.1158/0008-5472.CAN-08-1218
  2. Castello G, Scala S, Palmieri G, et al (2010). HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol, 134, 237-50. https://doi.org/10.1016/j.clim.2009.10.007
  3. Chen J, Li G, Meng H, et al (2012). Up regulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother, 61, 101-8. https://doi.org/10.1007/s00262-011-1094-3
  4. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  5. Cui L, Liu XX, Jiang Y, et al (2012). Comparative study on transcatheter arterial chemoembolization, portal vein embolization and high intensity focused ultrasound sequential therapy for patients. Asian Pac J Cancer Prev,13, 6257-61. https://doi.org/10.7314/APJCP.2012.13.12.6257
  6. Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75. https://doi.org/10.7314/APJCP.2014.15.8.3369
  7. Farazi PA and DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87. https://doi.org/10.1038/nrc1934
  8. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52. https://doi.org/10.7314/APJCP.2012.13.3.743
  9. Gomaa AI, Hashim MS, Waked I (2014). Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One, 9, e90929. https://doi.org/10.1371/journal.pone.0090929
  10. He SL, Shen J, Sun XJ, et al (2013). Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol, 19, 4552-8. https://doi.org/10.3748/wjg.v19.i28.4552
  11. Huang JJ, Li YJ, Xia Y, et al (2013). Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer, 13, 222. https://doi.org/10.1186/1471-2407-13-222
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Kuang DM, Peng C, Zhao Q, et al (2010). Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol, 185, 1544-9. https://doi.org/10.4049/jimmunol.0904094
  14. Lee YY, Choi CH, Sung CO, et al (2012). Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol, 124, 92-7. https://doi.org/10.1016/j.ygyno.2011.09.034
  15. Li J, Jiang R, Liu WS, et al (2013). A large cohort study reveals the association of elevated peripheral blood lymphocyte-tomonocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One, 8, e83069. https://doi.org/10.1371/journal.pone.0083069
  16. Liu H, Pan Z, Li A, et al (2008). Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol, 5, 373-8. https://doi.org/10.1038/cmi.2008.46
  17. Lok AS, Seeff LB, Morgan TR, et al (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 136, 138-48. https://doi.org/10.1053/j.gastro.2008.09.014
  18. Louafi S, Boige V, Ducreux M, et al (2007). Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer, 109, 1384-90. https://doi.org/10.1002/cncr.22532
  19. Ma WJ, Wang HY and Teng LS (2013). Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol, 11, 212. https://doi.org/10.1186/1477-7819-11-212
  20. Ma TC, Shao HB, Xu Y, et al (2013). Three treatment methods via the hepatic artery for hepatocellular carcinoma-a retrospective study. Asian Pac J Cancer Prev, 14, 2491-4. https://doi.org/10.7314/APJCP.2013.14.4.2491
  21. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9. https://doi.org/10.7314/APJCP.2013.14.11.6955
  22. Peng SH, Deng H, Yang JF, et al (2005). Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol, 11, 6521-4.
  23. Qin S, Bai Y, Lim HY, et al (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 31, 3501-8. https://doi.org/10.1200/JCO.2012.44.5643
  24. Sasaki A, Iwashita Y, Shibata K, et al (2006). Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery, 139, 755-64. https://doi.org/10.1016/j.surg.2005.10.009
  25. Schimanski CC, Bahre R, Gockel I, et al (2006). Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer, 95, 210-7. https://doi.org/10.1038/sj.bjc.6603251
  26. Takai H, Kato A, Kato C, et al (2009). The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int, 29, 1056-64. https://doi.org/10.1111/j.1478-3231.2008.01968.x
  27. Wang Z, Wu XL, Zeng WZ et al (2013). Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 691-4. https://doi.org/10.7314/APJCP.2013.14.2.691
  28. Werno C, Menrad H, Weigert A, et al (2010). Knockout of HIF-$1\alpha$ in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis, 31, 1863-72. https://doi.org/10.1093/carcin/bgq088
  29. Yang HI, Lu SN, Liaw YF, et al (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 347, 168-74. https://doi.org/10.1056/NEJMoa013215
  30. Yang Y, Nagano H, Ota H, et al (2007). Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery, 141, 196-202. https://doi.org/10.1016/j.surg.2006.06.033
  31. Yu Q, Yu XF, Zhang SD, et al (2013). Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 5735-40. https://doi.org/10.7314/APJCP.2013.14.10.5735
  32. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31. https://doi.org/10.7314/APJCP.2013.14.9.5527
  33. Zhu XD, Zhang JB, Zhuang PY, et al (2008). High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol, 26, 2707-16. https://doi.org/10.1200/JCO.2007.15.6521

Cited by

  1. Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism vol.36, pp.10, 2015, https://doi.org/10.1007/s13277-015-3475-2
  2. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4593-6
  3. EHHM, a novel phenolic natural product from Livistona chinensis, induces autophagy-related apoptosis in hepatocellular carcinoma cells vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5178
  4. Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6420